Epidemiology Department, Epiconcept, Paris, France.
Instituto Nacional de Saúde Doutor Ricardo Jorge (INSA), Lisbon, Portugal.
Euro Surveill. 2022 Jul;27(30). doi: 10.2807/1560-7917.ES.2022.27.30.2200551.
By employing a common protocol and data from electronic health registries in Denmark, Navarre (Spain), Norway and Portugal, we estimated vaccine effectiveness (VE) against hospitalisation due to COVID-19 in individuals aged ≥ 65 years old, without previous documented infection, between October 2021 and March 2022. VE was higher in 65-79-year-olds compared with ≥ 80-year-olds and in those who received a booster compared with those who were primary vaccinated. VE remained high (ca 80%) between ≥ 12 and < 24 weeks after the first booster administration, and after Omicron became dominant.
我们采用丹麦、西班牙纳瓦拉、挪威和葡萄牙的电子健康注册中心的通用方案和数据,估算了 2021 年 10 月至 2022 年 3 月期间,≥65 岁、既往无记录感染的个体因 COVID-19 住院的疫苗有效性(VE)。与≥80 岁的老年人相比,65-79 岁的老年人以及接受加强针接种的老年人的 VE 更高。在首次加强针接种后≥12 周至<24 周以及奥密克戎成为主导病毒株后,VE 仍保持高位(约 80%)。